Nanoscope Therapeutics Taps Alcon Veteran as COO to Accelerate MOGENRY Commercialization
Event summary
- Nanoscope Therapeutics appointed Paul Hallen, former Alcon VP and Global Head of Retina, as Chief Operating Officer effective April 1, 2026.
- Hallen brings 30 years of ophthalmology experience spanning R&D, manufacturing, commercial strategy, and global franchise leadership.
- Appointment comes as Nanoscope advances its rolling Biologics License Application for MCO-010 (MOGENRY™) in retinitis pigmentosa.
- Company has secured multiple global regulatory designations including FDA Fast Track, Orphan Drug, and RMAT status.
- MOGENRY platform targets photoreceptor degeneration diseases including RP, Stargardt disease, and geographic atrophy.
The big picture
The appointment of an industry veteran with deep ophthalmology experience signals Nanoscope's serious intent to commercialize its optogenetic therapy platform. This move comes as the company navigates the complex regulatory landscape for orphan drug designations across multiple markets, positioning itself as a potential leader in vision restoration therapies. The strategic hire underscores the importance of operational readiness as Nanoscope prepares for potential FDA approval of its lead candidate MOGENRY.
What we're watching
- Regulatory Momentum
- Whether Nanoscope can maintain its rapid pace of global regulatory approvals across multiple jurisdictions.
- Commercial Execution
- How Hallen's operational expertise will translate to Nanoscope's commercial readiness for MOGENRY launch.
- Pipeline Expansion
- The pace at which Nanoscope advances its additional programs including geographic atrophy and Leber congenital amaurosis.
Related topics